Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Zepbound (tirzepatide) and Wegovy (semaglutide) are prescription drugs used for weight loss and weight management. Both drugs come as a liquid solution for injection under the skin. Zepbound and ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average ...

After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...